B-cells

Under normal circumstances, immune B-cells train T-cells, another type of immune cell, on which targets not to attack, preventing the development of neuromyelitis optica spectrum disorder (NMOSD), according to a study in mice. This training occurs in the thymus gland, a small organ behind the breastbone that works as…

Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy equecabtagene autoleucel in people with neuromyelitis optica spectrum disorder (NMOSD), IASO announced. NMOSD is an autoimmune disorder wherein the body’s immune system launches an inflammatory attack that damages parts…

Key players in B-cell signaling pathways and related inflammatory molecules were elevated in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with healthy people, a study found. The findings suggest that targeting this signaling pathway could show therapeutic promise in NMOSD, the researchers noted. The study,…

Self-reactive antibodies that cause most cases of neuromyelitis optica spectrum disorder (NMOSD) are released directly from immune B-cells in lymph nodes as opposed to cells in the bloodstream, a study has discovered. These findings implicate ongoing lymph node activity as the main driver of disease-causing antibody production in NMOSD.

InnoCare Pharma will soon launch a Phase 2 clinical trial in China to test orelabrutinib, its oral investigational Bruton tyrosine kinase (BTK) inhibitor, to treat neuromyelitis optica spectrum disorder (NMOSD). The announcement comes after China’s National Medical Products Administration approved the company’s request to conduct such a trial,…

Prior treatment with rituximab does not limit the effectiveness or safety of Uplizna (inebilizumab-cdon) in people with  neuromyelitis optica spectrum disorder (NMOSD), a further analysis of data from the N-MOmentum Phase 2/3 trial has found. Uplizna’s efficacy in preventing NMOSD attacks and its safety profile were comparable in trial…

Uplizna (inebilizumab-cdon), a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD), is now available in the U.S. through specialty distributor BioCareSD and specialty infusion pharmacy BioTek Remedys. The companies added the medication to their portfolio of specialty therapeutics to expand upon their product offering…

Treatment with Horizon Therapeutics’ Uplizna (inebilizumab) leads to a rapid and sustained drop in immune B-cells in adults with neuromyelitis optica spectrum disorder (NMOSD), data from the N-MOmentum Phase 2/3 clinical trial show. Notably, while all Uplizna-treated patients experienced significant clinical benefits, those with greater B-cell depletion showed lower…

Treatment with Horizon Therapeutics’ Uplizna (inebilizumab-cdon) was found safe and effective at reducing the frequency of attacks in African-American adults with neuromyelitis optica spectrum disorder (NMOSD), according to a retrospective analysis of the N-MOmentum clinical trial. These findings were presented in a poster at the 15th World Congress…